Yu Jian, Xu Wenbin, Dong Qian, Ji Qingwei, Cheng Min, Hu Desheng, Cai Yifan, Zeng Qiutang, Yu Kunwu
Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China; Hubei Provincial Engineering Research Center of Immunological Diagnosis and Therapy for Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.
Department of Cardiology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China.
Clin Immunol. 2023 Oct;255:109767. doi: 10.1016/j.clim.2023.109767. Epub 2023 Sep 7.
A persistent autoimmune and inflammatory response plays a critical role in the progression of atherosclerosis. The transcription factor forkhead box P3 (Foxp3)CD4 regulatory T cells (Foxp3 Tregs) attenuate atherosclerosis. Latency-associated peptide (LAP)CD4 T cells are a new class of Tregs whose role in atherosclerosis is unknown.
To investigate the function of CD4LAP Tregs in inhibiting inflammation and preventing atherosclerosis.
Depletion of CD4LAP Tregs results in aggravated inflammation and atherosclerotic lesions. Mechanistically, CD4LAP Treg depletion was associated with decreased M2-like macrophages and increased Th1 and Th17 cells, characterized by increased unstable plaque promotion and decreased expression of inflammation-resolving factors in both arteries and immune organs. In contrast, adoptive transfer of CD4LAP Tregs to ApoE mice or CD4ApoE mice led to decreased atherosclerotic lesions. Compared with control animals, adoptive transfer of CD4LAP Tregs induced M2-like macrophage differentiation within the atherosclerotic lesion and spleen, associated with increased collagen and α-SMA in plaques and decreased expression of MMP-2 and MMP-9. Mechanistic studies reveal that isolated CD4LAP Tregs exhibit a tolerance phenotype, with increased expression of inhibitory cytokines and coinhibitory molecules. After coculture with CD4LAP Tregs, monocytes/macrophages display typical features of M2 macrophages, including upregulated expression of CD206 and Arg-1 and decreased production of MCP-1, IL-6, IL-1β and TNF-α, which was almost abrogated by transwell and partially TGF-β1 neutralization. RNA-seq analysis showed different gene expression profiles between CD4LAP Tregs and LAPCD4 T cells and between CD4LAP Tregs of ApoE mice and CD4LAP Tregs of C57BL/6 mice, of which Fancd2 and IL4i1 may contribute to the powerful inhibitory properties of CD4LAP Tregs. Furthermore, the number and the suppressive properties of CD4LAP Tregs were impaired by oxLDL.
Our data indicate that the remaining CD4LAP Tregs play a protective role in atherosclerosis by modulating monocyte/macrophage differentiation and regulatory factors, which may partly explain the protective effect of T cells tolerance in atherosclerosis. Moreover, adoptive transfer of CD4LAP Tregs constitutes a novel approach to treat atherosclerosis.
持续的自身免疫和炎症反应在动脉粥样硬化进展中起关键作用。转录因子叉头框P3(Foxp3)+ CD4调节性T细胞(Foxp3 + Tregs)可减轻动脉粥样硬化。潜伏期相关肽(LAP)+ CD4 T细胞是一类新型Tregs,其在动脉粥样硬化中的作用尚不清楚。
研究CD4 + LAP Tregs在抑制炎症和预防动脉粥样硬化中的作用。
清除CD4 + LAP Tregs会导致炎症和动脉粥样硬化病变加重。机制上,CD4 + LAP Treg的清除与M2样巨噬细胞减少以及Th1和Th17细胞增加有关,其特征是不稳定斑块形成增加以及动脉和免疫器官中炎症消退因子的表达降低。相反,将CD4 + LAP Tregs过继转移到ApoE基因敲除小鼠或CD4基因敲除ApoE基因敲除小鼠中会导致动脉粥样硬化病变减少。与对照动物相比,过继转移CD4 + LAP Tregs可诱导动脉粥样硬化病变和脾脏内M2样巨噬细胞分化,这与斑块中胶原蛋白和α-SMA增加以及MMP-2和MMP-9表达降低有关。机制研究表明,分离出的CD4 + LAP Tregs表现出耐受表型,抑制性细胞因子和共抑制分子的表达增加。与CD4 + LAP Tregs共培养后,单核细胞/巨噬细胞表现出M2巨噬细胞的典型特征,包括CD206和精氨酸酶1(Arg-1)表达上调以及单核细胞趋化蛋白-1(MCP-1)、白细胞介素-6(IL-6)、白细胞介素-1β(IL-1β)和肿瘤坏死因子-α(TNF-α)产生减少,而这几乎被Transwell小室和部分转化生长因子-β1(TGF-β1)中和所消除。RNA测序分析显示,CD4 + LAP Tregs与LAP + CD4 T细胞之间以及ApoE基因敲除小鼠的CD4 + LAP Tregs与C57BL / 6小鼠的CD4 + LAP Tregs之间存在不同的基因表达谱,其中范可尼贫血互补组D2(Fancd2)和白细胞介素4诱导蛋白1(IL4i1)可能有助于CD4 + LAP Tregs强大的抑制特性。此外,氧化型低密度脂蛋白(oxLDL)会损害CD4 + LAP Tregs的数量和抑制特性。
我们的数据表明,剩余的CD4 + LAP Tregs通过调节单核细胞/巨噬细胞分化和调节因子在动脉粥样硬化中发挥保护作用,这可能部分解释了T细胞耐受在动脉粥样硬化中的保护作用。此外,过继转移CD4 + LAP Tregs构成了一种治疗动脉粥样硬化的新方法。